8 completed, 2 unknown, 2 withdrawn, 1 not yet recruiting. 14 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 8, Unknown 2, Withdrawn 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 6 | Completed 3, Unknown 2, Not yet recruiting 1 |
Follow 0.9% Normal saline: new trials by email Literature Review of 0.9% Normal saline trials Research Report on 0.9% Normal saline
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA） NCR100, 0.9% Normal saline - Knee Osteoarthritis | Phase 1 / Phase 2 | Not yet recruiting | Nuwacell Biotechnologies Co., Ltd. | 162 | 2025-02-20 | 2024-12-18 |
| A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients HH-006, 0.9% normal saline - Chronic Hepatitis B Virus Infection | Phase 1 | Completed | Huahui Health | 36 | 2024-12-20 | 2026-04-07 |
| Effect of Fluid Resuscitation on Lactate in Traumatic Injury Patients 3% hypertonic Saline, Ringer's lactated solution, 0.9% Normal saline - Fluid Resuscitation | Phase 1 / Phase 2 | Unknown | Assiut University | 150 | 2024-08-01 | 2024-04-17 |
| Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Ivermectin Injectable Solution, Injectable Placebo, Zinc - Coronavirus Infection, COVID | Phase 1 / Phase 2 | Unknown | Sohaib Ashraf | 180 | 2020-11-14 | 2021-02-17 |
| Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration) hzVSF-v13 (intravenous, single dose), hzVSF-v13 (subcutaneous, single dose), hzVSF-v13 (intravenous, multiple dose) - Healthy Volunteers | Phase 1 | Completed | ImmuneMed, Inc. | 72 | 2020-09-16 | 2024-02-15 |
| Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers hzVSF-v13, Placebo - Healthy | Phase 1 | Completed | ImmuneMed, Inc. | 56 | 2018-11-20 | 2021-04-27 |
| MANP in African Americans With Hypertension Placebo - 1st Cycle, MANP - 1st Cycle, MANP - 2nd Cycle - Hypertension, Resistant to Conventional Therapy | Phase 1 | Withdrawn | Mayo Clinic | 2018-05-01 | 2023-03-09 | |
| Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support CD-NP, Placebo - Heart Failure, Left Ventricular Assist Device | Phase 1 | Withdrawn | Mayo Clinic | 2017-09-30 | 2017-07-28 | |
| Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects IOP Injection, 0.9% normal saline - Magnetic Resonance Imaging | Phase 1 | Completed | MegaPro Biomedical Co. Ltd. | 24 | 2016-02-01 | 2018-08-17 |
| A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects CAZ-AVI, 0.9% Normal Saline - Healthy Volunteers | Phase 1 | Completed | Pfizer | 42 | 2013-10-01 | 2017-09-05 |
| Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan Clostridium difficile Toxoid Vaccine, 0.9% normal saline - Clostridium Difficile Infection | Phase 1 / Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 102 | 2013-07-01 | 2018-07-18 |
| Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery? Tranexamic Acid, Placebo - Adolescent Idiopathic Scoliosis | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 120 | 2013-01-01 | 2019-02-20 |
| TAP Block for Open Radical Prostatectomy. Normal saline via TAP catheters, Lidocaine via TAP catheters - Opioid Consumption, Incidence of Nausea and Vomiting | Phase 1 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 25 | 2010-08-01 | 2015-03-17 |
| Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication Trans sodium crocetinate (TSC), 0.9% normal saline - Intermittent Claudication | Phase 1 / Phase 2 | Completed | Diffusion Pharmaceuticals Inc | 48 | 2008-08-01 | 2011-07-29 |
Atherosclerosis (1) · COVID-19 (1) · Clostridium Infections (1) · Coronavirus Infections (1) · Heart Failure (1) · Hemorrhage (1) · Hepatitis B, Chronic (1) · Hypertension Resistant to Conventional Therapy (1) · Intermittent Claudication (1) · Osteoarthritis, Knee (1) · Pain, Postoperative (1) · Peripheral Arterial Disease (1) · Vomiting (1)
ImmuneMed, Inc. (2) · Mayo Clinic (2) · Assiut University (1) · Boston Children's Hospital (1) · Diffusion Pharmaceuticals Inc (1) · Huahui Health (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · MegaPro Biomedical Co. Ltd. (1) · Nuwacell Biotechnologies Co., Ltd. (1) · Pfizer (1) · Sanofi Pasteur, a Sanofi Company (1) · Sohaib Ashraf (1)
United States (3) · China (2) · Australia (1) · Canada (1) · Japan (1) · Pakistan (1) · South Korea (1) · Taiwan (1)
Franco Carli, Professor (1) · Furong Qiu (1) · In-Jin Jang, M.D (1) · Moneeb Ashraf, MBBS (1) · Muhammad Ashraf, PhD (1) · Paul M McKie, M.D. (1) · Rheun-Chuan Lee (1) · Shoaib Ashraf, PhD (1) · Sohaib Ashraf, MBBS (1) · Susan Goobie, MD, FRCPC (1) · Tomoko Ichiki, M.D.Ph.D. (1)
PMID 21364458, PMID 22003000, PMID 23371895, PMID 29116880, PMID 30221827, PMID 34488858